Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells

Alaina C. Larson,Shelby M. Knoche,Gabrielle L. Brumfield,Kenadie R. Doty,Benjamin D. Gephart,Promise R. Moore-Saufley,Joyce C. Solheim

DOI: https://doi.org/10.3390/ijms25063211

IF: 5.6

2024-03-12

International Journal of Molecular Sciences

Abstract:Pancreatic cancer is a lethal disease, harboring a five-year overall survival rate of only 13%. Current treatment approaches thus require modulation, with attention shifting towards liberating the stalled efficacy of immunotherapies. Select chemotherapy drugs which possess inherent immune-modifying behaviors could revitalize immune activity against pancreatic tumors and potentiate immunotherapeutic success. In this study, we characterized the influence of gemcitabine, a chemotherapy drug approved for the treatment of pancreatic cancer, on tumor antigen presentation by human leukocyte antigen class I (HLA-I). Gemcitabine increased pancreatic cancer cells' HLA-I mRNA transcripts, total protein, surface expression, and surface stability. Temperature-dependent assay results indicated that the increased HLA-I stability may be due to reduced binding of low affinity peptides. Mass spectrometry analysis confirmed changes in the HLA-I-presented peptide pool post-treatment, and computational predictions suggested improved affinity and immunogenicity of peptides displayed solely by gemcitabine-treated cells. Most of the gemcitabine-exclusive peptides were derived from unique source proteins, with a notable overrepresentation of translation-related proteins. Gemcitabine also increased expression of select immunoproteasome subunits, providing a plausible mechanism for its modulation of the HLA-I-bound peptidome. Our work supports continued investigation of immunotherapies, including peptide-based vaccines, to be used with gemcitabine as new combination treatment modalities for pancreatic cancer.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the ability of pancreatic cancer cells to present tumor antigens, so as to enhance the effect of immunotherapy. Specifically, the research focuses on how the chemotherapeutic drug Gemcitabine regulates the expression of human leukocyte antigen class I (HLA - I), thereby improving the tumor antigen presentation of pancreatic cancer cells. Through this research, the author hopes to find the potential mechanism of the combined use of Gemcitabine and immunotherapy, in order to develop new combined treatment methods to fight pancreatic cancer.

### Background Information
- **Pancreatic cancer** is a fatal disease, with a 5 - year survival rate of only 13%.
- **Gemcitabine** is a commonly used chemotherapeutic drug for treating pancreatic cancer, but its efficacy is limited, and new treatment strategies need to be explored.
- The application effect of **immunotherapy** in pancreatic cancer is not good, mainly due to the immunosuppressive characteristics of the pancreatic cancer microenvironment.
- **HLA - I** molecules are responsible for presenting endogenous peptides to cytotoxic T cells and are the key to initiating T - cell - mediated tumor cell lysis.

### Research Objectives
- **Evaluate the effect of Gemcitabine on HLA - I expression**: Research how Gemcitabine affects the mRNA transcription, total protein level, surface expression and surface stability of HLA - I in pancreatic cancer cells.
- **Analyze the effect of Gemcitabine on the HLA - I - binding peptide pool**: Through mass spectrometry analysis and computational prediction, explore the changes in peptides presented by HLA - I after Gemcitabine treatment and their immunogenicity.
- **Explore the effect of Gemcitabine on the expression of immunoproteasome subunits**: Research whether Gemcitabine regulates the HLA - I - binding peptide pool by increasing the expression of specific immunoproteasome subunits.

### Main Findings
- **Gemcitabine increases the mRNA transcription, total protein level, surface expression and surface stability of HLA - I in pancreatic cancer cells**.
- **The results of temperature - dependent experiments indicate** that Gemcitabine may improve the surface stability of HLA - I by reducing the binding of low - affinity peptides.
- **Mass spectrometry analysis confirms** that after Gemcitabine treatment, the pool of peptides presented by HLA - I has changed, and computational prediction shows that these peptides have higher affinity and immunogenicity.
- **Gemcitabine increases the expression of specific immunoproteasome subunits**, which may be one of the mechanisms by which it regulates the HLA - I - binding peptide pool.

### Conclusion
This research supports the continuous exploration of new combined treatment models of using Gemcitabine in combination with immunotherapy (such as peptide - based vaccines) to improve the treatment effect of pancreatic cancer.